Corona virus vaccine. Agreements with Indian and Pakistani companies for the manufacture of American company's remediation

A US pharmaceutical company has entered into agreements with five South Asian pharmaceutical companies to manufacture code-19 remedial savory.

These agreements have been signed between Gilead and five pharmaceutical companies in India and Pakistan and the medicine manufactured here will be supplied to 127 countries of the world.

The experimental use of remediator in many hospitals around the world eliminated the symptoms caused by the corona virus in ten days instead of fifteen days.

The antiviral drug was originally developed to treat Ebola

The drug eliminates the enzymes in the human body that need the virus to reproduce in its cells.

A statement from Glade said the five companies would be provided with licensed remedial technology to enable large-scale production of the drug.

The statement added that no royalties or compensation will be levied on these licenses unless the World Health Organization declares an end to the emergency caused by Code 19 or any other drug or vaccine developed and Not accepted for treatment.

These agreements are with Supply Limited, Ferrosens Laboratories, Heathrow Labs Limited, Jubilant Life Sciences and Mellon.

Speaking to the BBC, the managing director of Heathrow, a private company based in Hyderabad, India, said it was too early to tell the price of the drug.

"The situation will be clear by June," said Wamsi Krishnabandi.

When he hopes that the drug will be used in government institutions under the supervision of doctors. The aim is to become self-sufficient in this medicine so that if it is decided to use this medicine in India, it will be available in large quantities in the country. he said.

Heathrow Lab is valued at more than ایک 1 billion and is the world's largest manufacturer of antiviral drugs, providing medicine to five million HIV / AIDS patients. Heathrow Lab manufactures more than 300 different medicines in its 36 laboratories around the world

India's medical science and drug control authorities must first declare that they allow the use of the drug in any way.

A senior scientist at the Indian Council of Medical Research has said that if Indian companies start developing the drug, they will consider allowing its use.

"Preliminary observational data shows that the drug is effective," said Raman Gangakdikar. We will wait for the results of the World Health Organization experiments and see if another company makes further progress.

Remedies were tested by the US National Institute of Allergy and Infectious Diseases with 1,063 participants. Some patients were given this medicine and some placebo.

Dr. Anthony Fauchi, head of the US agency, said the data clearly showed that the drug was very effective in reducing the duration of the disease.

These results prove that the drug is blocking the virus and is now opening the way for us to have the ability to treat the disease. he said.

But it is unknown at this time what he will do after leaving the post.

The mortality rate was 8% for patients receiving remedial treatment, while the mortality rate for placebo was 11%. This difference is not so great that scientists can say that this difference is due to medicine.